264 related articles for article (PubMed ID: 15985612)
1. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
Ryman-Rasmussen JP; Nichols DE; Mailman RB
Mol Pharmacol; 2005 Oct; 68(4):1039-48. PubMed ID: 15985612
[TBL] [Abstract][Full Text] [Related]
2. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
[TBL] [Abstract][Full Text] [Related]
3. Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
Fujita S; Lee J; Kiguchi M; Uchida T; Cools AR; Waddington JL; Koshikawa N
Eur J Pharmacol; 2006 May; 538(1-3):94-100. PubMed ID: 16682023
[TBL] [Abstract][Full Text] [Related]
4. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
Rosenzweig-Lipson S; Bergman J
J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
[TBL] [Abstract][Full Text] [Related]
6. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
[TBL] [Abstract][Full Text] [Related]
7. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Blanchet P; Bédard PJ; Britton DR; Kebabian JW
J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
[TBL] [Abstract][Full Text] [Related]
9. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
10. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
[TBL] [Abstract][Full Text] [Related]
11. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency.
Lewis MM; Watts VJ; Lawler CP; Nichols DE; Mailman RB
J Pharmacol Exp Ther; 1998 Jul; 286(1):345-53. PubMed ID: 9655879
[TBL] [Abstract][Full Text] [Related]
12. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Campbell BM; Kreipke CW; Walker PD
Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
[TBL] [Abstract][Full Text] [Related]
13. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
Mottola DM; Laiter S; Watts VJ; Tropsha A; Wyrick SD; Nichols DE; Mailman RB
J Med Chem; 1996 Jan; 39(1):285-96. PubMed ID: 8568818
[TBL] [Abstract][Full Text] [Related]
14. Dopamine acutely decreases type 3 Na(+)/H(+) exchanger activity in renal OK cells through the activation of protein kinases A and C signalling cascades.
Gomes P; Soares-da-Silva P
Eur J Pharmacol; 2004 Mar; 488(1-3):51-9. PubMed ID: 15044035
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice.
Desai RI; Terry P; Katz JL
Pharmacol Biochem Behav; 2005 Aug; 81(4):843-8. PubMed ID: 16000217
[TBL] [Abstract][Full Text] [Related]
16. Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists.
Watts VJ; Lawler CP; Gonzales AJ; Zhou QY; Civelli O; Nichols DE; Mailman RB
Synapse; 1995 Oct; 21(2):177-87. PubMed ID: 8584979
[TBL] [Abstract][Full Text] [Related]
17. A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?
Isacson R; Kull B; Wahlestedt C; Salmi P
Neuroscience; 2004; 124(1):33-42. PubMed ID: 14960337
[TBL] [Abstract][Full Text] [Related]
18. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
19. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
Clark D; White FJ
Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
[TBL] [Abstract][Full Text] [Related]
20. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.
Gleason SD; Witkin JM
Behav Pharmacol; 2004 Feb; 15(1):85-9. PubMed ID: 15075630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
